WeTrials
Active, not recruiting

A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)

What is this study?

This study is testing a personalized cancer vaccine called mRNA-4157 combined with an immunotherapy drug called pembrolizumab, compared to pembrolizumab alone. Researchers want to see if this combination helps prevent high-risk skin cancer from coming back after surgery.

Who can participate?

You might be eligible if you recently had high-risk skin cancer completely removed by surgery and are currently cancer-free. Participants also need to be well enough to carry out normal daily activities and have a tumor tissue sample available for testing.

What will happen?

Participants will receive either the combination of the experimental vaccine and immunotherapy or immunotherapy alone. Your health and any side effects will be closely monitored by the study team throughout the process.

Where and when?

This study takes place at medical centers in locations such as Tucson, Arizona, and California. The study is currently active, meaning it is underway for enrolled participants, but it is not currently recruiting new people.

Key Points
  • 1Tests a personalized cancer vaccine alongside standard immunotherapy
  • 2Aims to prevent high-risk skin cancer from returning after surgery
  • 3Comparing combination treatment against immunotherapy alone

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Melanoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.